ARDELYX, INC.
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
ARDX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0396971071
- LEI:
- Country:
- United States of America
- Address:
- 34175 ARDENWOOD BLVD., 94555 FREMONT
- Website:
- https://www.ardelyx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Ardelyx targets conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia in adult patients with Chronic Kidney Disease (CKD) on dialysis. Its key commercial products include IBSRELA® (tenapanor) and XPHOZAH®.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ARDELYX, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ARDELYX, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ARDELYX, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
